TXNIP and COVID-19: Despite previous studies showing quercetin and resveratrol, inhibitors of thioredoxin-interacting protein (TXNIP), as potential therapies for COVID-19 (49, 50), our observation of robust TXNIP downregulation in severe patients suggested that these inhibitors may exhibit reduced performance in these treatments to a certain degree.